Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Clinical Trial

NIH Co-funds First New HIV Vaccine Efficacy Study in Seven Years

aids-hiv-vaccineBethesda, MD, November 29, 2016 — The National Institutes of Health (NIH) yesterday announced that the first HIV vaccine efficacy study to launch anywhere in seven years is now testing whether an experimental vaccine regimen safely prevents HIV infection among South African adults.

The study, called HVTN 702, involves a new version of the only HIV vaccine candidate ever shown to provide some protection against the virus.

HVTN 702 aims to enroll 5,400 men and women, making it the largest and most advanced HIV vaccine clinical trial to take place in South Africa, where more than 1,000 people become infected with HIV every day. Continue reading

Rutgers Biomedical Chancellor Brian Strom’s Paper Explores Why Clinical Trial-Data Sharing Off to a Slow Start

Dr. Brian Strom

Dr. Brian Strom

New Brunswick, NJ, November 2, 2016 — For many years, doctors, scientists and researchers have urged that clinical drug trial data be shared to accelerate medical advances in treating multiple diseases.

But two years after free patient data became available in a major data-sharing project, the biggest surprise is how little it is being used.

“Given the risks patients are taking and given the data being collected, there’s an ethical imperative to make maximum use of it,” said Brian L. Strom, chancellor of Rutgers Biomedical and Health Sciences. “That’s why it’s frustrating that more people are not using it and we don’t fully know why.” Continue reading